<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156478">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019992</url>
  </required_header>
  <id_info>
    <org_study_id>CSU-ICU-2013-01</org_study_id>
    <nct_id>NCT02019992</nct_id>
  </id_info>
  <brief_title>Investigation of Plasma Mitochondrial DNA Level in Septic Patients</brief_title>
  <official_title>Plasma Levels of Mitochondrial DNA in Patients Presenting to ICU With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central South University</source>
  <oversight_info>
    <authority>China: Ethics Committee, Central South University</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the plasma levels of mtDNA in ICU department patients with and without sepsis
      and evaluate their association with severity, systemic inflammation and outcomes. Plasma
      from control, septic and severe septic patients will be collected. The level of mtDNA and
      systemic cytokine will be measured.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical protocol:

      Patients were enrolled into one of three cohorts: (i) sepsis defined as suspected infection
      and systemic inflammatory response, (ii) septic shock defined as sepsis plus hypotension,
      and (iii) control defined as non-infected patients without systemic inflammatory response.

      Methods:

      Plasma levels of mtDNAs were measured using real-time quantitative polymerase chain
      reaction. Levels of mtDNAs were compared among each group, and linear regression was used to
      assess the association between mtDNAs, IL-6, TNF a and IL-1b in patients with sepsis. The
      correlation between plasma mtDNA and severity, systemic inflammation and outcomes will be
      analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>change from baseline in plasma mtDNA in septic patients at 7 days</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change from baseline in plasma mtDNA in septic patients at 7 days will be measured by real-time PCR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in plasma IL-6, TNF a and IL-1b level in septic patients at 7 days</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The change from baseline in plasma IL-6, TNF a and IL-1b level in septic patients at 7 days will be measured by ELISA.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sepsis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>sepsis</arm_group_label>
    <description>sepsis defined as suspected infection and systemic inflammatory response</description>
  </arm_group>
  <arm_group>
    <arm_group_label>severe sepsis</arm_group_label>
    <description>sepsis with organ dysfunction or septic shock defined as sepsis plus hypotension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>control defined as non-infected patients without systemic inflammatory response.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sepsis and severe septic patients enrolled in 2014 will be collected.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sepsis and severe sepsis was according to the following guild-line.
             &quot;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis
             and Septic Shock: 2012&quot;

        Exclusion Criteria:

          -  Patients lost following-up. Patients who refuse to sign the consent form.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>lemeng zhang, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lemeng zhang, md</last_name>
    <phone>8673185064389</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yuhang ai, ma</last_name>
    <phone>8673184327074</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiangya Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>lemeng zhang, md</last_name>
      <phone>8673185064389</phone>
    </contact>
    <contact_backup>
      <last_name>yuhang ai, md</last_name>
      <phone>8673284327974</phone>
    </contact_backup>
    <investigator>
      <last_name>lemeng zhang, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central South University</investigator_affiliation>
    <investigator_full_name>lemeng zhang</investigator_full_name>
    <investigator_title>md</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>mitochondrial DNA</keyword>
  <keyword>systemic inflammation</keyword>
  <keyword>outcome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
